CADTH PHARMACEUTICAL REVIEW

Economic Report (Sample)

GENERIC DRUG NAME (BRAND NAME)
(Sponsor)
Indication: Text

Version: 1.0
Publication Date: Month XX, Year
Report Length: 19 Pages
Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
# Table of Contents

List of Tables.................................................................................................................. 4  
List of Figures .................................................................................................................. 5  
Abbreviations ................................................................................................................... 6  
Executive Summary ......................................................................................................... 7  
  Conclusions .................................................................................................................... 9  
Stakeholder Input Relevant to the Economic Review ...................................................... 10  
Economic Review ............................................................................................................. 11  
  Economic Evaluation ..................................................................................................... 11  
  Budget Impact Analysis ................................................................................................. 11  
  Issues for Consideration ............................................................................................... 12  
  Overall Conclusions...................................................................................................... 12  
Appendix 1: Cost Comparison Table ............................................................................. 13  
Appendix 2: Submission Quality .................................................................................... 14  
Appendix 3: Detailed Information on the Submitted Economic Evaluation .................. 15  
  Detailed Results of the Sponsor’s Base Case ............................................................... 15  
Appendix 4: CADTH Detailed Reanalyses and Sensitivity Analyses of the Economic Evaluation .................................................................................................................. 16  
  Detailed Results of CADTH Base Case ...................................................................... 16  
  Scenario Analyses ........................................................................................................ 16  
APPENDIX 5: Detailed Information on the Submitted BIA ........................................... 17  
  Analytic Framework Including Data Sources and Inputs ............................................. 17  
  Detailed Results of Sponsor’s BIA .............................................................................. 17  
Appendix 6: CADTH Detailed Reanalyses and Sensitivity Analyses of the BIA .......... 18
List of Tables
List of Figures
Abbreviations
The executive summary is comprised of three tables (Table 1: Background; Table 2: Economic Evaluation; and Table 3: Budget Impact Assessment) and a conclusion.

Executive Summary

Table 1: Summary of Background Information

<table>
<thead>
<tr>
<th>Drug product</th>
<th>Submitted price</th>
<th>Health Canada-approved indication</th>
<th>NOC date</th>
<th>Reimbursement request</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 2: Summary of Economic Evaluation

<table>
<thead>
<tr>
<th>Economic evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of economic evaluation</td>
</tr>
<tr>
<td>Target population(s)</td>
</tr>
<tr>
<td>Treatment(s)</td>
</tr>
<tr>
<td>Comparator(s)</td>
</tr>
<tr>
<td>Perspective</td>
</tr>
<tr>
<td>Outcome(s)</td>
</tr>
<tr>
<td>Time horizon</td>
</tr>
<tr>
<td>Key data source</td>
</tr>
<tr>
<td>Submitted results for base case</td>
</tr>
<tr>
<td>Key limitations</td>
</tr>
<tr>
<td>CADTH reanalysis results</td>
</tr>
</tbody>
</table>
### Table 3: Summary of BIA

<table>
<thead>
<tr>
<th>Budget impact analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target population(s)</td>
</tr>
<tr>
<td>Treatment(s)</td>
</tr>
<tr>
<td>Comparator(s)</td>
</tr>
<tr>
<td>Perspective</td>
</tr>
<tr>
<td>Time horizon</td>
</tr>
<tr>
<td>Expected market size</td>
</tr>
<tr>
<td>Expected market uptake for [drug under review]</td>
</tr>
<tr>
<td>Results for base case</td>
</tr>
<tr>
<td>Key limitations</td>
</tr>
<tr>
<td>CADTH estimate(s)</td>
</tr>
</tbody>
</table>

**Conclusions**
Stakeholder Input Relevant to the Economic Review
Economic Review

Economic Evaluation
Summary of Sponsor’s Economic Evaluation
Overview

Model Structure

Model Inputs

Summary of Sponsor’s Economic Evaluation Results

Base-Case Results

Sensitivity and Scenario Analysis Results

CADTH Appraisal of the Sponsor’s Economic Evaluation

CADTH Reanalyses of the Economic Evaluation
Base-Case Results

Scenario Analysis Results

Budget Impact Analysis
Summary of Sponsor’s BIA
Overview

Analytic Framework

Summary of the Sponsor’s BIA Results
CADTH Appraisal of the Sponsor’s BIA

CADTH Reanalyses of the BIA

*Budget Impact Results*

**Issues for Consideration**

**Overall Conclusions**
Appendix 1: Cost Comparison Table
## Appendix 2: Submission Quality

### Table 4: Submission Quality

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population is relevant, with no critical intervention missing, and no relevant outcome missing</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Model has been adequately programmed and has sufficient face validity</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Model structure is adequate for decision problem</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Data incorporation into the model has been done adequately (e.g., parameters for probabilistic analysis)</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Parameter and structural uncertainty were adequately assessed; analyses were adequate to inform the decision problem</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>The submission was well organized and complete; the information was easy to locate (clear and transparent reporting; technical documentation available in enough details)</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
</tbody>
</table>
Appendix 3: Detailed Information on the Submitted Economic Evaluation

Detailed Results of the Sponsor’s Base Case
Appendix 4: CADTH Detailed Reanalyses and Sensitivity Analyses of the Economic Evaluation

Detailed Results of CADTH Base Case

Scenario Analyses
APPENDIX 5: Detailed Information on the Submitted BIA

Analytic Framework Including Data Sources and Inputs

Detailed Results of Sponsor’s BIA
Appendix 6: CADTH Detailed Reanalyses and Sensitivity Analyses of the BIA